Back to search results

A Study to Investigate the Safety and Tolerability of Oral INR731 Single Agent or in Combination With Androgen Receptor Pathway Inhibitor (ARPI) in Patients With Metastatic Prostate Cancer

Abroad (travel likely)RecruitingPHASE1

Conditions

Metastatic Castration-resistant Prostate Cancer (mCRPC)

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Mary Crowley Cancer Research, Dallas, Texas, United States

    Contact: Study coordinator (Pramitha Kondancheri) · Pramitha.RarothKondancheri@scri.com · 972-566-3000
    Contact: Principal Investigator (Reva Schneider)

  • Novartis Investigative Site, Melbourne, Victoria, Australia

  • Novartis Investigative Site, Hirakata, Osaka, Japan

View source on ClinicalTrials.gov(opens in a new tab)